Most Read

Ivonescimab is a potential first-in-class investigational PD-1/VEGF bi-specific antibody. It is the company’s other new antibody with a priority review following the marketing approval of cadonilimab. After the

The first-in-class, investigational monoclonal antibody ALE.C04 has been developed for targeting exposed CLDN1 in specific on cancer cells. It is designed to treat cancer by remodelling of the

The regulator has provided a prescription drug user fee act (PDUFA) date of fourth quarter this year for the review. The sNDA is being reviewed under two initiatives

These therapies include an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. Talvey recently received the US Food and Drug Administration’s approval for the same indication in

MAb-AR20.5 is an IgG1k type murine monoclonal antibody that attaches specifically to the circulating and tumour-associated antigen (MUC1) expressed on pancreatic cancer cells. It is said to become

The regulator has provided the Prescription Drug User Fee Act (PDUFA) date of 20 December this year for the review. Currently approved under accelerated approval, TARPEYO is developed

The Series B round was co-led by Redmile Group and Bain Capital Life Sciences. It saw participation of new and existing investors including RA Capital Management, Samsara BioCapital,

As per the terms of the deal, Sprint will receive $3m as upfront payment. Day One will also reimburse Sprint for pre-clinical research and development expenses. Additionally, Sprint

The regulatory agency has granted priority review for this NDA with Prescription Drug User Fee Act (PDUFA) target action date of 22 February next year. It earlier granted